Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
-
ORLANDO, Fla., Sept. 17, 2025 (GLOBE NEWSWIRE) -- It is estimated that more than 13 million Americans struggle with post-traumatic stress disorder (PTSD). A new study, Hyperbaric Oxygen Therapy for...
-
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company,...
-
MAPS selects Changemark as CRO for $12.9M Phase 2 cannabis PTSD study in Veterans, advancing toward Q1 2026 treatment start.
-
PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results
-
Sparkling Ice and Giant Eagle have teamed up to sponsor a PTSD service dog through K9s For Warriors, whose mission is to end veteran suicide.
-
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial.
-
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug...
-
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the...
-
PharmAla warns the public that it does not sell MDMA to consumers, and to be on guard for illegitimate and fake products falsely being sold online.